Peter Sandercock and IST-3 Author: International Journal of Stroke Acute ischemic stroke is a major public health burden and globally a common cause of death and disability Be a guest on this podcast Language: en-pi Genres: Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Get all podcast data

Listen Now...

Peter Sandercock and IST-3
Tuesday, 17 August, 2010

Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.

We also recommend:

MonsterTalk
Blake Smith

Evolution: artificial selection and domestication - for iBooks
The Open University

World Stroke Academy, Hypertension & Stroke
World Stroke Academy

Soif de savoir
Soif de savoir

LMU Physik 1 für Chemiker (PN1) WS2015/16
Prof. Dr. Jan Lipfert

Meteorología-Previsión del tiempo
canaltiempo21

Catholic Health Prayers and Reflections
Catholic Health Association of the United States

Antarcticast
michel kluger

DigiLabour
Rafael Grohmann

Utelias mieli
Helsingin yliopisto

Lead with Nature
Dan Gardoqui

Existential Teenager
Oscar Blair